Chemical Name:9-Azabicyclo[3.3.1]nonan-3-one Hydrochloride

CAS.NO:72761-60-5

Synonyms:9-azabicyclo[3.3.1]nonan-3-one,hydrochloride

Molecular Formula:C₈H₁₄ClNO

Molecular Weight:175.65600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:277.2ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:29.10000

Exact Mass:175.07600

LogP:1.99080

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 9-azabicyclo[3.3.1]nonan-3-one,hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9-azabicyclo[3.3.1]nonan-3-one,hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-azabicyclo[3.3.1]nonan-3-one,hydrochloride Use and application,9-azabicyclo[3.3.1]nonan-3-one,hydrochloride technical grade,usp/ep/jp grade.

Related News: AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 9-Azabicyclo[3.3.1]nonan-3-one Hydrochloride manufacturer Take penicillin industrial salt and vitamin C as examples. They are the two strategic varieties of chemical raw materials in China, and they are also representatives of severe overcapacity. 9-Azabicyclo[3.3.1]nonan-3-one Hydrochloride supplier According to statistics, in the ten years from 2008 to 2017, a total of 13 China Class 1 small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China. 9-Azabicyclo[3.3.1]nonan-3-one Hydrochloride vendor AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. 9-Azabicyclo[3.3.1]nonan-3-one Hydrochloride factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.